Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGR-1202 + Ruxolitinib in Myelofibrosis, Polycythemia Vera, and MDS/MPN
NCT02493530Phase 1Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2015
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbralisib in myelofibrosis (MF), polycythemia vera (PV) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Safety of TGR1202 in combination with ruxolitinib at 12 months. Started Jul 2015; status: completed.
02
Drugs
umbralisib
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT02493530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493530.